{"id": "article-161479_0", "title": "Dutasteride -- Indications", "content": "Dutasteride was approved by the US Food and Drug Administration (FDA) in 2001 and has also been used off-label for several conditions.", "contents": "Dutasteride -- Indications. Dutasteride was approved by the US Food and Drug Administration (FDA) in 2001 and has also been used off-label for several conditions."}
{"id": "article-161479_1", "title": "Dutasteride -- Indications -- FDA-Approved Indications", "content": "The FDA approved dutasteride in 2001 for the management of symptomatic benign prostatic hyperplasia to alleviate symptoms and decrease the risk of acute urinary retention and the potential need for surgery. [1] Dutasteride is approved for this indication both as a monotherapy as well as a dual therapy with the alpha-blocker tamsulosin. [1] [2] [3] As per the American Urological Association (AUA 2021) guidelines, the use of 5\u03b1-reductase inhibitors (5-ARIs) like dutasteride, either alone or in combination with \u03b1-blockers, is strongly recommended for the management of benign prostatic hyperplasia/lower urinary tract symptoms. This suggestion aims to prevent the progression of benign prostatic hyperplasia and urinary tract symptoms, decrease the risks of urinary retention, and reduce the requirement for future prostate-related surgery. [4]", "contents": "Dutasteride -- Indications -- FDA-Approved Indications. The FDA approved dutasteride in 2001 for the management of symptomatic benign prostatic hyperplasia to alleviate symptoms and decrease the risk of acute urinary retention and the potential need for surgery. [1] Dutasteride is approved for this indication both as a monotherapy as well as a dual therapy with the alpha-blocker tamsulosin. [1] [2] [3] As per the American Urological Association (AUA 2021) guidelines, the use of 5\u03b1-reductase inhibitors (5-ARIs) like dutasteride, either alone or in combination with \u03b1-blockers, is strongly recommended for the management of benign prostatic hyperplasia/lower urinary tract symptoms. This suggestion aims to prevent the progression of benign prostatic hyperplasia and urinary tract symptoms, decrease the risks of urinary retention, and reduce the requirement for future prostate-related surgery. [4]"}
{"id": "article-161479_2", "title": "Dutasteride -- Indications -- Off-Label Uses", "content": "Dutasteride is prescribed off-label for androgenic alopecia, also known as male pattern hair loss. [5] Although not approved by the FDA, randomized clinical trials yielded significant evidence in support of dutasteride efficacy in mild to moderate androgenetic alopecia in men. [6] [7] [8] [9] This was not only in comparison to placebo but also in comparison to finasteride. This 5\u03b1-reductase inhibitor has received official approval for use in patients with androgenic alopecia. [10] While off-label use requires careful consideration and adherence to evidence-based practices, dutasteride may provide a valuable alternative for managing this condition. Importantly, the use of dutasteride as prevention against prostate cancer in high-risk men was found to reduce the incidence of prostate cancer compared with a placebo. [11] [12] Although not adequately supported, literature reports other off-label uses in the treatment of excessive hair growth in women with hirsutism and as hormonal therapy in transgender individuals. [13] [14] [15] As per AUA guidelines, clinicians may consider 5\u03b1-reductase inhibitors such as dutasteride as a treatment option to minimize intraoperative bleeding and the perioperative requirement for blood transfusion following procedures like transurethral resection of the prostate (TURP) or other surgical interventions for BPH. [4]", "contents": "Dutasteride -- Indications -- Off-Label Uses. Dutasteride is prescribed off-label for androgenic alopecia, also known as male pattern hair loss. [5] Although not approved by the FDA, randomized clinical trials yielded significant evidence in support of dutasteride efficacy in mild to moderate androgenetic alopecia in men. [6] [7] [8] [9] This was not only in comparison to placebo but also in comparison to finasteride. This 5\u03b1-reductase inhibitor has received official approval for use in patients with androgenic alopecia. [10] While off-label use requires careful consideration and adherence to evidence-based practices, dutasteride may provide a valuable alternative for managing this condition. Importantly, the use of dutasteride as prevention against prostate cancer in high-risk men was found to reduce the incidence of prostate cancer compared with a placebo. [11] [12] Although not adequately supported, literature reports other off-label uses in the treatment of excessive hair growth in women with hirsutism and as hormonal therapy in transgender individuals. [13] [14] [15] As per AUA guidelines, clinicians may consider 5\u03b1-reductase inhibitors such as dutasteride as a treatment option to minimize intraoperative bleeding and the perioperative requirement for blood transfusion following procedures like transurethral resection of the prostate (TURP) or other surgical interventions for BPH. [4]"}
{"id": "article-161479_3", "title": "Dutasteride -- Mechanism of Action -- Mechanism", "content": "Dutasteride is an aza-steroid medication belonging to the class of 5\u03b1-reductase inhibitors. Dutasteride is classified as a potent, competitive, and irreversible mechanism-based inhibitor of types I and II of 5\u03b1-reductase. The enzyme 5\u03b1-reductase intracellularly converts testosterone to a more potent androgen known as dihydrotestosterone (DHT). [16] The type I 5\u03b1-reductase is primarily found in skin-related sebaceous glands, sweat glands, and keratinocytes and synthesizes about 33% of circulating DHT. The type II 5\u03b1-reductase isozyme is predominantly found in male genital tract-associated structures such as the epididymis, vas deferens, seminal vesicles, and prostate. Type II\u00a0is responsible for about 66% of circulating DHT. [17] [18] Given the dual inhibition of the\u00a02 types of 5\u03b1-reductases, dutasteride causes a near-complete suppression of DHT. More than a 90% reduction of serum DHT levels is seen with dutasteride, whereas only a 70% reduction of serum DHT levels is caused by finasteride. [19] [20]", "contents": "Dutasteride -- Mechanism of Action -- Mechanism. Dutasteride is an aza-steroid medication belonging to the class of 5\u03b1-reductase inhibitors. Dutasteride is classified as a potent, competitive, and irreversible mechanism-based inhibitor of types I and II of 5\u03b1-reductase. The enzyme 5\u03b1-reductase intracellularly converts testosterone to a more potent androgen known as dihydrotestosterone (DHT). [16] The type I 5\u03b1-reductase is primarily found in skin-related sebaceous glands, sweat glands, and keratinocytes and synthesizes about 33% of circulating DHT. The type II 5\u03b1-reductase isozyme is predominantly found in male genital tract-associated structures such as the epididymis, vas deferens, seminal vesicles, and prostate. Type II\u00a0is responsible for about 66% of circulating DHT. [17] [18] Given the dual inhibition of the\u00a02 types of 5\u03b1-reductases, dutasteride causes a near-complete suppression of DHT. More than a 90% reduction of serum DHT levels is seen with dutasteride, whereas only a 70% reduction of serum DHT levels is caused by finasteride. [19] [20]"}
{"id": "article-161479_4", "title": "Dutasteride -- Mechanism of Action -- Mechanism", "content": "By establishing a stable complex with 5\u03b1-reductase, dutasteride inhibits the conversion of testosterone to DHT, which exhibits a higher affinity to androgen receptors. By acting on those receptors, DHT modulates genes that dictate cell proliferation. [21] DHT seems to be the principal androgen responsible for the maturation of the prostate gland during development and its growth in later life through normal masculinization of the external genitalia. [22] Thus, reducing the serum DHT levels decreases prostatic volume and increases epithelial apoptosis. Accordingly, long-term use of dutasteride has been shown to reduce prostatic volume and provide relief of reduced urinary tract symptoms associated with an enlarged prostate. In addition, dutasteride has been established to decrease the frequency with which patients must undergo hyperplasia-related surgical procedures.", "contents": "Dutasteride -- Mechanism of Action -- Mechanism. By establishing a stable complex with 5\u03b1-reductase, dutasteride inhibits the conversion of testosterone to DHT, which exhibits a higher affinity to androgen receptors. By acting on those receptors, DHT modulates genes that dictate cell proliferation. [21] DHT seems to be the principal androgen responsible for the maturation of the prostate gland during development and its growth in later life through normal masculinization of the external genitalia. [22] Thus, reducing the serum DHT levels decreases prostatic volume and increases epithelial apoptosis. Accordingly, long-term use of dutasteride has been shown to reduce prostatic volume and provide relief of reduced urinary tract symptoms associated with an enlarged prostate. In addition, dutasteride has been established to decrease the frequency with which patients must undergo hyperplasia-related surgical procedures."}
{"id": "article-161479_5", "title": "Dutasteride -- Mechanism of Action -- Pharmacokinetics", "content": "Absorption: After administration of a single dose of 0.5 mg dutasteride, the peak concentration (Tmax) was attained within 120 to 180 minutes. [23] Studies have shown that this Tmax increases significantly in patients who take the drug with food. Dutasteride takes approximately 3 to 6 months to reach a steady-state concentration. [24] Daily drug administration achieved 65% of steady-state concentration after 1 month and 90% after 3 months. Making patients aware of this estimation can help set realistic expectations in managing symptomatic BPH using dutasteride. [25] The oral bioavailability of 0.5 mg dutasteride formulation is approximately 60%. [24] [26] Although the maximum plasma level was found to be reduced by up to 15% when dutasteride was given with food, this effect is clinically irrelevant.", "contents": "Dutasteride -- Mechanism of Action -- Pharmacokinetics. Absorption: After administration of a single dose of 0.5 mg dutasteride, the peak concentration (Tmax) was attained within 120 to 180 minutes. [23] Studies have shown that this Tmax increases significantly in patients who take the drug with food. Dutasteride takes approximately 3 to 6 months to reach a steady-state concentration. [24] Daily drug administration achieved 65% of steady-state concentration after 1 month and 90% after 3 months. Making patients aware of this estimation can help set realistic expectations in managing symptomatic BPH using dutasteride. [25] The oral bioavailability of 0.5 mg dutasteride formulation is approximately 60%. [24] [26] Although the maximum plasma level was found to be reduced by up to 15% when dutasteride was given with food, this effect is clinically irrelevant."}
{"id": "article-161479_6", "title": "Dutasteride -- Mechanism of Action -- Pharmacokinetics", "content": "Distribution: Dutasteride exhibits a large volume of distribution between 300 L and 500 L, indicating that it is extensively distributed throughout the body, including in semen. After daily oral administration of 0.5 mg dutasteride in healthy subjects for 12 months, approximately 12% of serum dutasteride was partitioned into semen. [24] [27] Dutasteride is 99% bound to albumin and 96.6% bound to \u03b11-acid glycoprotein in the serum, indicating extensive protein binding and potentially significant drug-drug interaction issues.", "contents": "Dutasteride -- Mechanism of Action -- Pharmacokinetics. Distribution: Dutasteride exhibits a large volume of distribution between 300 L and 500 L, indicating that it is extensively distributed throughout the body, including in semen. After daily oral administration of 0.5 mg dutasteride in healthy subjects for 12 months, approximately 12% of serum dutasteride was partitioned into semen. [24] [27] Dutasteride is 99% bound to albumin and 96.6% bound to \u03b11-acid glycoprotein in the serum, indicating extensive protein binding and potentially significant drug-drug interaction issues."}
{"id": "article-161479_7", "title": "Dutasteride -- Mechanism of Action -- Pharmacokinetics", "content": "Metabolism: Dutasteride undergoes extensive hepatic metabolism mediated by CYP3A4/5. Several minor and major hydroxylated metabolites are formed. The activity of 6-\u03b2-hydroxy-dutasteride is comparable to that of dutasteride. [28]", "contents": "Dutasteride -- Mechanism of Action -- Pharmacokinetics. Metabolism: Dutasteride undergoes extensive hepatic metabolism mediated by CYP3A4/5. Several minor and major hydroxylated metabolites are formed. The activity of 6-\u03b2-hydroxy-dutasteride is comparable to that of dutasteride. [28]"}
{"id": "article-161479_8", "title": "Dutasteride -- Mechanism of Action -- Pharmacokinetics", "content": "Excretion: Less than 1% of the medication is eliminated renally. Approximately 45% of the medication is eliminated in feces (5% unchanged and 40% as metabolites). [23] The elimination half-life of dutasteride is up to 5 weeks, significantly longer than finasteride, which lasts 5 to 6 hours. Total body clearance is approximately 0.6 L/hour, indicating apparent linear clearance. [25]", "contents": "Dutasteride -- Mechanism of Action -- Pharmacokinetics. Excretion: Less than 1% of the medication is eliminated renally. Approximately 45% of the medication is eliminated in feces (5% unchanged and 40% as metabolites). [23] The elimination half-life of dutasteride is up to 5 weeks, significantly longer than finasteride, which lasts 5 to 6 hours. Total body clearance is approximately 0.6 L/hour, indicating apparent linear clearance. [25]"}
{"id": "article-161479_9", "title": "Dutasteride -- Mechanism of Action -- Onset and Duration of Response", "content": "Significant symptom improvement is evident in patients receiving 0.5 mg daily after 3 to 12 months of treatment. [25] Substantial reductions in the prostate volume are apparent after 1 month and increases in maximum urine flow rate are evident after 3 months. With daily doses of 0.5 mg, median serum DHT levels fell by 85% and 90% after 1 and 2 weeks, respectively.", "contents": "Dutasteride -- Mechanism of Action -- Onset and Duration of Response. Significant symptom improvement is evident in patients receiving 0.5 mg daily after 3 to 12 months of treatment. [25] Substantial reductions in the prostate volume are apparent after 1 month and increases in maximum urine flow rate are evident after 3 months. With daily doses of 0.5 mg, median serum DHT levels fell by 85% and 90% after 1 and 2 weeks, respectively."}
{"id": "article-161479_10", "title": "Dutasteride -- Administration", "content": "Available Dosage Forms and Strengths: Dutasteride is administered as an oral capsule. [29] A fixed-dose combination of dutasteride/tamsulosin is available for the treatment of benign prostatic hyperplasia.\u00a0The regular strength used is 0.5 mg/capsule.", "contents": "Dutasteride -- Administration. Available Dosage Forms and Strengths: Dutasteride is administered as an oral capsule. [29] A fixed-dose combination of dutasteride/tamsulosin is available for the treatment of benign prostatic hyperplasia.\u00a0The regular strength used is 0.5 mg/capsule."}
{"id": "article-161479_11", "title": "Dutasteride -- Administration", "content": "Adult Dosage: For benign prostatic hyperplasia, dutasteride is used as monotherapy (0.5 mg oral once daily) or as a combination therapy with tamsulosin (0.5 mg dutasteride and 0.4 mg tamsulosin once daily).", "contents": "Dutasteride -- Administration. Adult Dosage: For benign prostatic hyperplasia, dutasteride is used as monotherapy (0.5 mg oral once daily) or as a combination therapy with tamsulosin (0.5 mg dutasteride and 0.4 mg tamsulosin once daily)."}
{"id": "article-161479_12", "title": "Dutasteride -- Administration -- Specific Patient Populations", "content": "Hepatic Impairment: No dosage adjustments are provided in the manufacturer's labeling. Dutasteride is extensively hepatically metabolized, and plasma concentration could be increased in hepatic impairment. Dutasteride has been associated with transient serum aminotransferase elevations in controlled trials, comparable to or lower than those observed with placebo therapy, and rarely necessitating dose modification. [30] Renal Impairment: No dutasteride dose adjustment is necessary in patients with renal impairment.", "contents": "Dutasteride -- Administration -- Specific Patient Populations. Hepatic Impairment: No dosage adjustments are provided in the manufacturer's labeling. Dutasteride is extensively hepatically metabolized, and plasma concentration could be increased in hepatic impairment. Dutasteride has been associated with transient serum aminotransferase elevations in controlled trials, comparable to or lower than those observed with placebo therapy, and rarely necessitating dose modification. [30] Renal Impairment: No dutasteride dose adjustment is necessary in patients with renal impairment."}
{"id": "article-161479_13", "title": "Dutasteride -- Administration -- Specific Patient Populations", "content": "Pregnancy considerations: Given the mechanism of action and results of animal reproduction studies, in-utero exposure to dutasteride may cause fetal harm. Dutasteride has been shown to cause congenital disabilities in male children secondary to its inhibition of DHT. [31] Therefore, dutasteride is contraindicated during pregnancy. The medication should not be handled by patients who are or who may be pregnant. If contact with a broken capsule occurs, the exposed area must be immediately washed with water and soap because dutasteride can be absorbed through the skin.", "contents": "Dutasteride -- Administration -- Specific Patient Populations. Pregnancy considerations: Given the mechanism of action and results of animal reproduction studies, in-utero exposure to dutasteride may cause fetal harm. Dutasteride has been shown to cause congenital disabilities in male children secondary to its inhibition of DHT. [31] Therefore, dutasteride is contraindicated during pregnancy. The medication should not be handled by patients who are or who may be pregnant. If contact with a broken capsule occurs, the exposed area must be immediately washed with water and soap because dutasteride can be absorbed through the skin."}
{"id": "article-161479_14", "title": "Dutasteride -- Administration -- Specific Patient Populations", "content": "Breastfeeding considerations: Available evidence is not sufficient for determining infant risk when used during breastfeeding. Dutasteride's absence or presence in breast milk has not been demonstrated. [32] Pediatric patients: Dutasteride is not approved for use in pediatric patients, and its safety and effectiveness in this population have not been established. Older\u00a0patients: Dutasteride is safe for older adults. Patients older than 65 do not require dose adjustments based on the pharmacokinetic parameters of the 0.5 mg dosage form.", "contents": "Dutasteride -- Administration -- Specific Patient Populations. Breastfeeding considerations: Available evidence is not sufficient for determining infant risk when used during breastfeeding. Dutasteride's absence or presence in breast milk has not been demonstrated. [32] Pediatric patients: Dutasteride is not approved for use in pediatric patients, and its safety and effectiveness in this population have not been established. Older\u00a0patients: Dutasteride is safe for older adults. Patients older than 65 do not require dose adjustments based on the pharmacokinetic parameters of the 0.5 mg dosage form."}
{"id": "article-161479_15", "title": "Dutasteride -- Administration -- Specific Patient Populations", "content": "Male Patients: Dutasteride has been shown to decrease semen volume, total sperm count, and sperm motility. [33] The effects on total sperm count were irreversible after 24 weeks of follow-up. The effects on fertility remain unknown.", "contents": "Dutasteride -- Administration -- Specific Patient Populations. Male Patients: Dutasteride has been shown to decrease semen volume, total sperm count, and sperm motility. [33] The effects on total sperm count were irreversible after 24 weeks of follow-up. The effects on fertility remain unknown."}
{"id": "article-161479_16", "title": "Dutasteride -- Adverse Effects -- Adverse Drug Reactions", "content": "Some patients taking dutasteride may experience sexual dysfunction, which can manifest as impotence (0.3% to 12%), decreased libido (up to 4.5%), or difficulty ejaculating (up to 7.8%). [20] [34] [35] These sexual adverse effects may persist despite discontinuing dutasteride. Furthermore, some patients have reported experiencing acute urinary retention while using dutasteride. [36] The impact of dutasteride on fertility has not been widely studied, but preliminary results indicate that mild reductions in semen parameters may be present while taking the medication. [37]", "contents": "Dutasteride -- Adverse Effects -- Adverse Drug Reactions. Some patients taking dutasteride may experience sexual dysfunction, which can manifest as impotence (0.3% to 12%), decreased libido (up to 4.5%), or difficulty ejaculating (up to 7.8%). [20] [34] [35] These sexual adverse effects may persist despite discontinuing dutasteride. Furthermore, some patients have reported experiencing acute urinary retention while using dutasteride. [36] The impact of dutasteride on fertility has not been widely studied, but preliminary results indicate that mild reductions in semen parameters may be present while taking the medication. [37]"}
{"id": "article-161479_17", "title": "Dutasteride -- Adverse Effects -- Adverse Drug Reactions", "content": "One adverse effect less commonly associated with dutasteride is gynecomastia (\u22641%), a condition characterized by the development of breast tissue in male patients. [38] [34] This results from the inhibition of testosterone's conversion to DHT and the subsequent increase in the peripheral conversion of testosterone to estrogen. [19] Increased estrogen is known to cause increased accumulation of breast tissue in male patients. [39] Patients should be informed of the potential risk of gynecomastia before initiating dutasteride treatment.", "contents": "Dutasteride -- Adverse Effects -- Adverse Drug Reactions. One adverse effect less commonly associated with dutasteride is gynecomastia (\u22641%), a condition characterized by the development of breast tissue in male patients. [38] [34] This results from the inhibition of testosterone's conversion to DHT and the subsequent increase in the peripheral conversion of testosterone to estrogen. [19] Increased estrogen is known to cause increased accumulation of breast tissue in male patients. [39] Patients should be informed of the potential risk of gynecomastia before initiating dutasteride treatment."}
{"id": "article-161479_18", "title": "Dutasteride -- Adverse Effects -- Adverse Drug Reactions", "content": "Depression and its persistence following discontinuation is an established adverse effect of finasteride, the other \u03b1-reductase inhibitor. [40] While there is comparatively less evidence linking dutasteride to depression, it is recommended to monitor patients for mood changes or signs of suicidal ideation while taking dutasteride. However, the link between dutasteride and depression remains under investigation. [41]", "contents": "Dutasteride -- Adverse Effects -- Adverse Drug Reactions. Depression and its persistence following discontinuation is an established adverse effect of finasteride, the other \u03b1-reductase inhibitor. [40] While there is comparatively less evidence linking dutasteride to depression, it is recommended to monitor patients for mood changes or signs of suicidal ideation while taking dutasteride. However, the link between dutasteride and depression remains under investigation. [41]"}
{"id": "article-161479_19", "title": "Dutasteride -- Adverse Effects -- Adverse Drug Reactions", "content": "Less frequently, dutasteride has been associated with dizziness, headaches, and gastrointestinal upset. [19] Rare but serious adverse events include angioedema, cutaneous hypersensitivity, and prostate cancer.", "contents": "Dutasteride -- Adverse Effects -- Adverse Drug Reactions. Less frequently, dutasteride has been associated with dizziness, headaches, and gastrointestinal upset. [19] Rare but serious adverse events include angioedema, cutaneous hypersensitivity, and prostate cancer."}
{"id": "article-161479_20", "title": "Dutasteride -- Adverse Effects -- Test Interactions", "content": "Prostate-specific antigen (PSA) levels drop in treated patients. After about 3 months of treatment, PSA levels stabilize to a baseline of approximately 50% of the pre-treatment value.", "contents": "Dutasteride -- Adverse Effects -- Test Interactions. Prostate-specific antigen (PSA) levels drop in treated patients. After about 3 months of treatment, PSA levels stabilize to a baseline of approximately 50% of the pre-treatment value."}
{"id": "article-161479_21", "title": "Dutasteride -- Adverse Effects -- Drug-Drug Interactions", "content": "Dutasteride is not significantly affected by the coadministration with \u03b1-blockers (eg, terazosin, doxazosin, tamsulosin). [24] Alpha-blockers are often used in conjunction with dutasteride to manage benign prostatic hyperplasia.", "contents": "Dutasteride -- Adverse Effects -- Drug-Drug Interactions. Dutasteride is not significantly affected by the coadministration with \u03b1-blockers (eg, terazosin, doxazosin, tamsulosin). [24] Alpha-blockers are often used in conjunction with dutasteride to manage benign prostatic hyperplasia."}
{"id": "article-161479_22", "title": "Dutasteride -- Adverse Effects -- Drug-Drug Interactions", "content": "However, other drug-drug interactions may exist, although they may vary in severity. Concurrent use of dutasteride and itraconazole may result in increased dutasteride exposure and an increased risk of dutasteride-related adverse effects. Furthermore, simultaneous administration of ceritinib (strong CYP3A inhibitor) and CYP3A substrates in dutasteride may increase CYP3A substrate exposure. Concurrent use of dutasteride and fluconazole may also result in increased dutasteride exposure and risk for toxicity.", "contents": "Dutasteride -- Adverse Effects -- Drug-Drug Interactions. However, other drug-drug interactions may exist, although they may vary in severity. Concurrent use of dutasteride and itraconazole may result in increased dutasteride exposure and an increased risk of dutasteride-related adverse effects. Furthermore, simultaneous administration of ceritinib (strong CYP3A inhibitor) and CYP3A substrates in dutasteride may increase CYP3A substrate exposure. Concurrent use of dutasteride and fluconazole may also result in increased dutasteride exposure and risk for toxicity."}
{"id": "article-161479_23", "title": "Dutasteride -- Adverse Effects -- Drug-Drug Interactions", "content": "Although the severity is moderate, it is essential to know that concurrent use of dutasteride and ciprofloxacin, ketoconazole, verapamil, diltiazem, ritonavir, or cimetidine may increase dutasteride plasma concentrations. [42]", "contents": "Dutasteride -- Adverse Effects -- Drug-Drug Interactions. Although the severity is moderate, it is essential to know that concurrent use of dutasteride and ciprofloxacin, ketoconazole, verapamil, diltiazem, ritonavir, or cimetidine may increase dutasteride plasma concentrations. [42]"}
{"id": "article-161479_24", "title": "Dutasteride -- Adverse Effects -- Drug-Food Interactions", "content": "Maximum serum concentrations of dutasteride are decreased by 10% to 15% when taken with food, which is not clinically significant. Thus, the medication is to be taken without regard to meals.", "contents": "Dutasteride -- Adverse Effects -- Drug-Food Interactions. Maximum serum concentrations of dutasteride are decreased by 10% to 15% when taken with food, which is not clinically significant. Thus, the medication is to be taken without regard to meals."}
{"id": "article-161479_25", "title": "Dutasteride -- Contraindications", "content": "Use of dutasteride during pregnancy or in women who may become pregnant is contraindicated. Likewise, use in children is contraindicated. [24] Dutasteride is contraindicated in patients with clinically significant hypersensitivity to dutasteride, excipients,\u00a0or finasteride. [43]", "contents": "Dutasteride -- Contraindications. Use of dutasteride during pregnancy or in women who may become pregnant is contraindicated. Likewise, use in children is contraindicated. [24] Dutasteride is contraindicated in patients with clinically significant hypersensitivity to dutasteride, excipients,\u00a0or finasteride. [43]"}
{"id": "article-161479_26", "title": "Dutasteride -- Contraindications -- Box Warnings", "content": "No boxed warnings have been reported at the time of writing this article.", "contents": "Dutasteride -- Contraindications -- Box Warnings. No boxed warnings have been reported at the time of writing this article."}
{"id": "article-161479_27", "title": "Dutasteride -- Contraindications -- Warnings and Precautions", "content": "As a precaution, donating blood during or for\u00a06 months following treatment cessation should be avoided due to the risk of administration to a transfusion recipient who is pregnant. Dutasteride may cause fetal harm. Therefore, capsules should not be handled by pregnant patients or those of childbearing potential due to the potential risk of fetal exposure and potential risk to a male fetus from cutaneous absorption. If contact occurs, the area should be immediately washed with soap and water.", "contents": "Dutasteride -- Contraindications -- Warnings and Precautions. As a precaution, donating blood during or for\u00a06 months following treatment cessation should be avoided due to the risk of administration to a transfusion recipient who is pregnant. Dutasteride may cause fetal harm. Therefore, capsules should not be handled by pregnant patients or those of childbearing potential due to the potential risk of fetal exposure and potential risk to a male fetus from cutaneous absorption. If contact occurs, the area should be immediately washed with soap and water."}
{"id": "article-161479_28", "title": "Dutasteride -- Contraindications -- Warnings and Precautions", "content": "Dutasteride undergoes extensive metabolism by the hepatic cytochrome P450 enzyme system. Inhibition of this metabolism can significantly increase the concentration of the drug, possibly increasing the risk of adverse effects. As a result, dutasteride should be avoided in patients with severe liver disease, while it should be used with caution in patients with milder hepatic impairment. [30] The medication has been reported to affect male fertility, as mentioned above. [33]", "contents": "Dutasteride -- Contraindications -- Warnings and Precautions. Dutasteride undergoes extensive metabolism by the hepatic cytochrome P450 enzyme system. Inhibition of this metabolism can significantly increase the concentration of the drug, possibly increasing the risk of adverse effects. As a result, dutasteride should be avoided in patients with severe liver disease, while it should be used with caution in patients with milder hepatic impairment. [30] The medication has been reported to affect male fertility, as mentioned above. [33]"}
{"id": "article-161479_29", "title": "Dutasteride -- Contraindications -- Warnings and Precautions", "content": "Clinicians should monitor PSA levels periodically to monitor the response to therapy. The increase in PSA levels may indicate prostate cancer. [44] Lastly, other urological conditions that may cause similar symptoms of BPH should be considered before initiation.", "contents": "Dutasteride -- Contraindications -- Warnings and Precautions. Clinicians should monitor PSA levels periodically to monitor the response to therapy. The increase in PSA levels may indicate prostate cancer. [44] Lastly, other urological conditions that may cause similar symptoms of BPH should be considered before initiation."}
{"id": "article-161479_30", "title": "Dutasteride -- Monitoring", "content": "The exact therapeutic index of dutasteride is not well-defined, and patients taking it should be made aware of the associated adverse effects. [24] Patients should report any breast enlargement or tenderness as well as any sexual side effects.  Patients should be counseled on the fact that these sexual side effects may persist after discontinuation of dutasteride. [34] [40]", "contents": "Dutasteride -- Monitoring. The exact therapeutic index of dutasteride is not well-defined, and patients taking it should be made aware of the associated adverse effects. [24] Patients should report any breast enlargement or tenderness as well as any sexual side effects.  Patients should be counseled on the fact that these sexual side effects may persist after discontinuation of dutasteride. [34] [40]"}
{"id": "article-161479_31", "title": "Dutasteride -- Monitoring", "content": "Clinicians should monitor patients for signs of an allergic reaction to dutasteride, including itching, skin rash, lips, tongue, or face swelling. Patients should stop taking dutasteride and inform their healthcare team if any of these symptoms present.", "contents": "Dutasteride -- Monitoring. Clinicians should monitor patients for signs of an allergic reaction to dutasteride, including itching, skin rash, lips, tongue, or face swelling. Patients should stop taking dutasteride and inform their healthcare team if any of these symptoms present."}
{"id": "article-161479_32", "title": "Dutasteride -- Monitoring", "content": "Prostate cancer and urological diseases should be ruled out before initiating therapy and periodically. As mentioned earlier, PSA is expected to decrease by approximately 50% following 3 to 6 months of treatment. Therefore, a new baseline should be established to evaluate potential cancer-related changes to PSA. The American Urological Association Symptom Index (AUA-SI)/International Prostate Symptom Score (IPSS) should be used to assess the severity of benign prostatic hyperplasia. [4] Improvement in the signs and symptoms of benign prostatic hyperplasia, such as increased urinary flow, indicates efficacy.", "contents": "Dutasteride -- Monitoring. Prostate cancer and urological diseases should be ruled out before initiating therapy and periodically. As mentioned earlier, PSA is expected to decrease by approximately 50% following 3 to 6 months of treatment. Therefore, a new baseline should be established to evaluate potential cancer-related changes to PSA. The American Urological Association Symptom Index (AUA-SI)/International Prostate Symptom Score (IPSS) should be used to assess the severity of benign prostatic hyperplasia. [4] Improvement in the signs and symptoms of benign prostatic hyperplasia, such as increased urinary flow, indicates efficacy."}
{"id": "article-161479_33", "title": "Dutasteride -- Toxicity -- Signs and Symptoms of Overdose", "content": "Single doses of 0.5 mg dutasteride for the management of benign prostatic hyperplasia or androgenic alopecia have exhibited a favorable safety profile with minimal significant adverse events. [24] There are no reports of toxicity following acute overdose. In studies, single doses of up to 40 mg (80 times the standard therapeutic dose) for\u00a07 days have been administered with no significant effects reported.", "contents": "Dutasteride -- Toxicity -- Signs and Symptoms of Overdose. Single doses of 0.5 mg dutasteride for the management of benign prostatic hyperplasia or androgenic alopecia have exhibited a favorable safety profile with minimal significant adverse events. [24] There are no reports of toxicity following acute overdose. In studies, single doses of up to 40 mg (80 times the standard therapeutic dose) for\u00a07 days have been administered with no significant effects reported."}
{"id": "article-161479_34", "title": "Dutasteride -- Toxicity -- Management of Overdose", "content": "While dutasteride overdose cases are rare, it is essential to acknowledge the potential for adverse drug reactions. In the absence of a well-established antidote for dutasteride overdose, treatment of overdose is symptomatic and supportive. Given the large volume of distribution and high protein binding, dialysis is unlikely to be beneficial. Medical attention should be sought immediately if an overdose is suspected. Allergic reactions can be treated with antihistamines with or without inhaled \u03b2-agonists and corticosteroids. [45] Treating severe anaphylaxis involves oxygen supplementation, airway management, epinephrine, IV fluids, and EKG monitoring. Further research may provide additional insights into the management of potential overdose.", "contents": "Dutasteride -- Toxicity -- Management of Overdose. While dutasteride overdose cases are rare, it is essential to acknowledge the potential for adverse drug reactions. In the absence of a well-established antidote for dutasteride overdose, treatment of overdose is symptomatic and supportive. Given the large volume of distribution and high protein binding, dialysis is unlikely to be beneficial. Medical attention should be sought immediately if an overdose is suspected. Allergic reactions can be treated with antihistamines with or without inhaled \u03b2-agonists and corticosteroids. [45] Treating severe anaphylaxis involves oxygen supplementation, airway management, epinephrine, IV fluids, and EKG monitoring. Further research may provide additional insights into the management of potential overdose."}
{"id": "article-161479_35", "title": "Dutasteride -- Enhancing Healthcare Team Outcomes", "content": "Benign prostatic hyperplasia (BPH) is a condition linked with lower urinary tract symptoms (LUTS), and it is becoming more prevalent among the aging population. Over the last 20 years, the morbidity related to BPH and BPH-associated LUTS has surged by a substantial 80%, underscoring the escalating significance of this condition. [46] UTS not only significantly impacts patient quality of life but also exhibits more pronounced effects on depression and anxiety compared to other chronic illnesses such as gout, diabetes, and hypertension. [47] [48] [49] Effectively managing BPH, especially when accompanied by LUTS, is crucial to address these challenges.", "contents": "Dutasteride -- Enhancing Healthcare Team Outcomes. Benign prostatic hyperplasia (BPH) is a condition linked with lower urinary tract symptoms (LUTS), and it is becoming more prevalent among the aging population. Over the last 20 years, the morbidity related to BPH and BPH-associated LUTS has surged by a substantial 80%, underscoring the escalating significance of this condition. [46] UTS not only significantly impacts patient quality of life but also exhibits more pronounced effects on depression and anxiety compared to other chronic illnesses such as gout, diabetes, and hypertension. [47] [48] [49] Effectively managing BPH, especially when accompanied by LUTS, is crucial to address these challenges."}
{"id": "article-161479_36", "title": "Dutasteride -- Enhancing Healthcare Team Outcomes", "content": "Clinically effective options for the management of symptomatic BPH include dutasteride and other 5\u03b1-reductase inhibitors. The suitability of dutasteride as a management choice depends on individual patient needs, health status, and ability to obtain and adhere to the prescribed medication. The multifaceted nature of patient quality of life in the context of BPH encompasses various factors, including education level, overall health, presence of chronic diseases, income, alcohol consumption, and physical activity. [50] Therefore, a comprehensive approach to BPH management is essential for success, requiring the collaboration of an interprofessional healthcare team. To assess a patient's eligibility for dutasteride therapy and ensure seamless integration with a comprehensive BPH management plan, clinicians (MDs, DOs, NPs, PAs), nurses, urologists, case workers, and pharmacists. The involvement of collaborative interprofessional teams holds significant potential for enhancing patient outcomes, minimizing adverse effects associated with BPH management, and delivering optimal patient care.", "contents": "Dutasteride -- Enhancing Healthcare Team Outcomes. Clinically effective options for the management of symptomatic BPH include dutasteride and other 5\u03b1-reductase inhibitors. The suitability of dutasteride as a management choice depends on individual patient needs, health status, and ability to obtain and adhere to the prescribed medication. The multifaceted nature of patient quality of life in the context of BPH encompasses various factors, including education level, overall health, presence of chronic diseases, income, alcohol consumption, and physical activity. [50] Therefore, a comprehensive approach to BPH management is essential for success, requiring the collaboration of an interprofessional healthcare team. To assess a patient's eligibility for dutasteride therapy and ensure seamless integration with a comprehensive BPH management plan, clinicians (MDs, DOs, NPs, PAs), nurses, urologists, case workers, and pharmacists. The involvement of collaborative interprofessional teams holds significant potential for enhancing patient outcomes, minimizing adverse effects associated with BPH management, and delivering optimal patient care."}
{"id": "article-161479_37", "title": "Dutasteride -- Review Questions", "content": "Access free multiple choice questions on this topic. Comment on this article.", "contents": "Dutasteride -- Review Questions. Access free multiple choice questions on this topic. Comment on this article."}